Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 27, 2023 | Last Trade: US$137.78 0.46 0.33

DUBLIN, Feb. 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences:

Cowen 43rd Annual Health Care Conference

Date: Tuesday, March 7, 2023
Location: Boston
Company management will participate in a fireside chat at 12:50 p.m. ET / 5:50 p.m. GMT
A live audio webcast may be accessed via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. A replay of the webcast will be available on the website for 30 days following the conference.

J.P. Morgan 12^th Annual Napa Valley Biotech Forum

Date: Tuesday, March 21, 2023
Location: San Francisco
Company management will participate in a fireside chat at 1:45 p.m. ET / 6:45 p.m. GMT

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
This email address is being protected from spambots. You need JavaScript enabled to view it.
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
This email address is being protected from spambots. You need JavaScript enabled to view it.
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Stock Quote

Last Trade:	US$137.78
Daily Change:	0.46 0.33
Daily Volume:	399,978
Market Cap:	US$8.360B

October 02, 2025 Jazz Pharmaceuticals: FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer September 22, 2025 Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses September 09, 2025 Jazz Pharmaceuticals: Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma August 20, 2025 Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 August 20, 2025 Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 LOAD MORE NEWS

Featured Stock

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE